LRCX vs RNA · P/E 71, rev $23.23B vs rev $22.6M
Lam Research Corp (LRCX) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
LRCX currently screens at market cap $467.94B and trailing P/E 70.9. RNA currently screens at market cap $217.5M.
Not investment advice. Open the LRCX and RNA stock pages for the full models.
Not investment advice.